The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2016, Pages

  Mhaskar, Rahul ^a   Wao, Hesborn ^a   Miladinovic, Branko ^a   Kumar, Ambuj ^a   Djulbegovic, Benjamin ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; ANTINEOPLASTIC AGENT; IRON;

CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFORMATION RETRIEVAL; IRON THERAPY; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT RESPONSE; ANEMIA; BLOOD; CHEMICALLY INDUCED; HEMATOPOIESIS; INTRAVENOUS DRUG ADMINISTRATION; NEOPLASMS; ORAL DRUG ADMINISTRATION; UTILIZATION;

ADMINISTRATION, ORAL; ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROCYTE TRANSFUSION; HEMATINICS; HEMATOPOIESIS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84973505662     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009624.pub2     Document Type: Review

References (89)

1. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. Journal of Clinical Oncology 2004;22(7):1301-7.
2. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. Journal of Clinical Oncology 2004;22(7):1301-7.
3. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. Journal of Clinical Oncology 2004;22(7):1301-7.
4. Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu T, Shao J, et al. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. American Journal of Hematology 2010;85(9):655-63.
5. Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Journal of Clinical Oncology 2008;26(10):1611-8.
6. Beguin Y, Maertens J, De Prijck B, Schots R, Frere P, Bonnet C, et al. Darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation: A prospective randomized multicenter trial. American Society of hematology Annual Meeting and Exposition. 2008.
7. Bellet RE, Ghazal H, Flam M, Drelichman A, Gabrail N, Woytowitz D, et al. A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy. Journal of Clinical Oncology, 2007 ASCO Annual Meetings Proceedings Part 1 2007;25(18S):9109.
8. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12(2):231-42.
9. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12(2):231-42.
10. Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. Journal of Clinical Oncology 2008;26(10):1619-25.
11. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. Journal of Clinical Oncology 2011;29(1):97-105. [PUBMED: 21098317]
12. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. Journal of Clinical Oncology 2011;29(1):97-105.
13. Agrawal SG, Lim C, Cavill I. Prospective targeted epoietin beta therapy for chemotherapy-associated anaemia achieves high response rates. Blood 2005;106:588.
14. Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecologic oncology 2013;131(3):679-82. [PUBMED: 24099839]
15. Auerbach M, Silberstein PT, Webb T, Averyanova S, Ciuleanu T, Cam L, et al. Darbepoetin alfa (DA) 500mcg or 300mcg once every three weeks with or without iron in patients (pts) with chemotherapy-induced anemia (CIA). Annals of Oncology 2008;19 (Suppl 8): viii:1-4.
16. Birgegard G, Osterborg A, Hedenus M. Functional iron deficiency effectively overcome by adjuvant IV iron during epoetin treatment. ASH Annual Meeting Abstract 2006;108(11):3725.
17. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecologic Oncology 2010;116(3):522-5. [PUBMED: 20051288]
18. Demarteau N, Annemans L, Mossman T, Bracco A. Cost-effectiveness of darbepoetin alfa (DA) 500 mcg every three weeks (Q3W) with IV iron compared to DA Q3W alone in cancer patients (pts) with chemotherapy-induced anaemia (CIA). Journal of Clinical Oncology (Meeting Abstracts) 2007;25(18):Suppl 19531.
19. Doherty EJ, Pappadakis J, Ryan K, Auerbach M. Intravenous iron improves efficacy and results in substantial savings in cost for patients receiving erythropoiesis-stimulating agents (ESAs) for chemotherapy-induced anemia. Journal of Clinical Oncology (Meeting Abstracts) May 2008;26(15):Suppl 20664.
20. Ferrari P, Nicolini A, Manca ML, Rossi G, Anselmi L, Conte M, et al. Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2012;66(6):414-8. [PUBMED: 22795809]
21. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21(4):627-32.
22. Hedenus M, Karlsson T, Ludwig H, Rzychon B, Felder M, Roubert B, et al. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Medical oncology (Northwood, London, England) 2014;31(12):302. [PUBMED: 25373320]
23. Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecologic Oncology 2007;105(1):199-204. [PUBMED: 17234260]
24. Lerchenmueller C, Husseini F, Gaede B, Mossman T, Suto T, Vanderbroek A. Intravenous (IV) iron supplementation in patients with chemotherapy-induced anemia (CIA) receiving darbepoetin alfa every 3 weeks (Q3W): Iron parameters in a randomized controlled trial. Blood 2006;108(11):1552.
25. Maccio A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. The Oncologist 2010;15(8):894-902. [PUBMED: 20647390]
26. Pinter T, Mossman T, Suto T, Vansteenkiste J. Effects of intravenous (IV) iron supplementation on responses to every-3-week (Q3W) darbepoetin alfa (DA) by baseline hemoglobin in patients (pts) with chemotherapy-induced anemia (CIA). Journal of Clinical Oncology (Meeting Abstracts) June 20, 2007;25(18):9106.
27. Savonije JH, van Groeningen CJ, van den Broek WJ, Rentinck ME, Corstens FH, Gundy C, et al. Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia. Cancer Investigation 2006;24(6):562-6. [PUBMED: 16982459]
28. Vandebroek A, Gaede B, Altintas S, Smith K, Yao B, Schupp M, et al. A randomized open-label study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with nonmyeloid malignancies receiving chemotherapy. Journal of Clinical Oncology (Meeting Abstracts) 2006;24(18):Suppl 8612.
29. NCT01145638. A study of intravenous iron isomaltoside 1000 (Monofer®) as mono therapy (without erythropoiesis stimulating agents) in comparison with oral iron sulfate in subjects with non-myeloid malignancies associated with chemotherapy induced anaemia (CIA). clinicaltrials.gov/show/NCT01145638 June 2010 (accessed July 2015).
30. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. The Oncologist 2008;13(Suppl 3):33-6. [PUBMED: 18458123]
31. Auerbach M. Should intravenous iron be the standard of care in oncology?. Journal of Clinical Oncology 2008;26(10):1579-81.
32. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrology Dialysis Transplantation 2005;20(7):1443-9. [PUBMED: 15855210]
33. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines 3: Rating the quality of evidence - introduction. Journal of Clinical Epidemiology 2011;64(4):401-6. [PUBMED: 21208779]
34. Barrett-Lee PJ, Ludwig H, Birgegard G, Bokemeyer C, Gascon P, Kosmidis PA, et al. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 2006;70(1):34-48. [PUBMED: 16493206]
35. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299(8):914-24. [PUBMED: 18314434]
36. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. The Lancet 2009;373(9674):1532-42.
37. Bohlius J, Tonia T, Nuesch E, Juni P, Fey MF, Egger M, et al. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. British Journal of Cancer 2014;111(1):33-45. [PUBMED: 24743705]
38. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. On the relative safety of parenteral iron formulations. Nephrology Dialysis Transplantation 2004;19(6):1571-5. [PUBMED: 15150356]
39. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrology Dialysis Transplantation 2006;21(2):378-82. [PUBMED: 16286429]
40. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
41. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. Journal of Clinical Oncology 1998;16(10):3412-25. [PUBMED: 9779721]
42. Eschbach JW. Iron requirements in erythropoietin therapy. Best Practices Research Clinical Haematology 2005;18(2):347-61.
43. Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. American Journal of Kidney Diseases 2001;37(4):743-9. [PUBMED: 11273874]
44. Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks. Cancer 2007;110(7):1629-40. [PUBMED: 17694552]
45. Gafter-Gvili A, Rozen-Zvi B, Vidal L, Leibovici L, Vansteenkiste J, Gafter U, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. Acta Oncologica 2013;52(1):18-29. [PUBMED: 22877242]
46. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. Journal of Clinical Oncology 1997;15(3):1218-34.
47. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. British Journal of Cancer 2010;102(2):301-15.
48. Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEpro. Version 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.
49. Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
50. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
51. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
52. Guyatt G, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines: 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [PUBMED: 21839614]
53. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82. [PUBMED: 21802904]
54. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence - risk of bias. Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
55. Henry DH, Brooks BJ Jr, Case DC Jr, Fishkin E, Jacobson R, Keller AM, et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. The Cancer Journal From Scientific American 1995;1(4):252-60. [PUBMED: 9166485]
56. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
57. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
58. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
59. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Archives of Internal Medicine 2008;168(21):2377-81. [PUBMED: 19029504]
60. Kitano T, Tada H, Nishimura T, Teramukai S, Kanai M, Nishimura T, et al. Prevalence and incidence of anemia in Japanese cancer patients receiving outpatient chemotherapy. International Journal of Hematology 2007;86(1):37-41. [PUBMED: 17675265]
61. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. The American Journal of Medicine 2004;116 Suppl 7A:11S-26S.
62. Leonard RC, Untch M, Von Koch F. Management of anaemia in patients with breast cancer: role of epoetin. Annals of Oncology 2005;16(5):817-24.
63. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology 2001;19(11):2865-74.
64. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer 2004;40(15):2293-306.
65. Mamula P, Piccoli DA, Peck SN, Markowitz JE, Baldassano RN. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition 2002;34(3):286-90.
66. Mancuso A, Migliorino M, De Santis S, Saponiero A, De Marinis F. Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Annals of Oncology 2006;17(1):146-50.
67. Mercadante S, Ferrera P, Villari P, David F, Giarratano A, Riina S. Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. Journal of Palliative Medicine 2009;12(1):60-3.
68. Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B. Role of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patients. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009624; CD009624]
69. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006-12.
70. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Cancer and treatment-related anemia. http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf (accessed 18 June 2010).
71. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: Cancer and treatment-related anemia. http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf (accessed 18 June 2010).
72. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata Journal 2006;6(1):40-57.
73. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Addition of iron to erythropoiesis-stimulating agents in cancer patients: A meta-analysis of randomized trials. Journal of Cancer Research and Clinical Oncology 2012;138(2):179-87. [PUBMED: 21972052]
74. Pujade-Lauraine E, Gascon P. The burden of anaemia in patients with cancer. Oncology 2004;67 Suppl 1:1-4. [PUBMED: 15489559]
75. Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, et al. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. Journal of Clinical Oncology 2006;24(22):3583-9.
76. The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.3. Copenhagen: The Cochrane Collaboration, 2014.
77. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Journal of Clinical Oncology 2002;20(19):4083-107.
78. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. Journal of Clinical Oncology 2008;26(1):132-49. [PUBMED: 17954713]
79. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Journal of Clinical Oncology 2010;28(32):4996-5010.
80. Schwartz RN. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols. American Journal of Health-System Pharmacy 2007;64(3 Suppl 2):S5-13.
81. Shander A, Spence RK, Auerbach M. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?. Transfusion 2010;50(3):719-32. [PUBMED: 19919555]
82. Shord SS, Hamilton JM Jr, Cuellar S. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia. Journal of Oncology Pharmacy Practice 2008;14(1):5-22. [PUBMED: 18337436]
83. Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer 2003;98(9):1786-801. [PUBMED: 14584059]
84. StataCorp LP. Stata Statistical Software. Version 11. College Station, TX: StataCorp LP, 2009.
85. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. [PUBMED: 12958120]
86. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. [PUBMED: 17555582]
87. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD003407.pub5; PUBMED: 23235597]
88. van Weert E, Hoekstra-Weebers J, Otter R, Postema K, Sanderman R, van der Schans C. Cancer-related fatigue: predictors and effects of rehabilitation. The Oncologist 2006;11(2):184-96. [PUBMED: 16476839]
89. White IR, Higgins JP. Meta-analysis with missing data. Stata Journal 2009;9(1):57.